Epigenic Therapeutics Announces Completion of $60 Million Series B Financing to Accelerate Clinical Development of Epigenetic Medicines
SHANGHAI, Sept. 8, 2025 /PRNewswire/ -- Epigenic Therapeutics ("Epigenic"), a clinical-stage innovative drug development company, today announced the completion of a $60 million Series B round of financing led by...
Read more